Category - Markets

Maxim Group raised its price target for Sophiris Bio (NASDAQ:SPHS) to $8 from $5, factoring in topsalysin data in prostate cancer at the end of the second quarter. The stock was quoted at $3.55 in afternoon trading on...

Ladenburg Thalmann initiated coverage of Zymeworks (NYSE:ZYME) with a “buy” rating and $25 price target. The stock closed at $15.84 on May 14. Zymeworks is developing bispecific/multifunctional biotherapeutics initially...

Maxim Group raised its price target for Coherus Biosciences (NASDAQ:CHRS) to $22 from $18 after the FDA has accepted for review the recently resubmitted BLA for CHS-1701 (Neulasta biosimilar). This is a Type I response...

Piper Jaffray upgraded Tandem Diabetes (NASDAQ:TNDM) to “overweight” from “neutral” and raised its price target to $13 from $8 after hosting meetings with the company’s CEO and CFO. The stock closed at $8.90 on April 11...

H.C. Wainwright upgraded Proteon Therapeutics (NASDAQ:PRTO) to “buy” from “neutral” and raised its price target to $3 from $2.30. “While investors may have written Proteon off after the failure of the PATENCY-1 study in...

BTIG upgraded TransEnterix (NASDAQ:TRXC) to “buy” with a price target of $3.50 after the company posted first quarter revenue above expectations. The stock closed at $1.83 on April 8. Dr. Sean Lavin writes that there...

IntelGenx Technologies (OTCQX:IGXT; TSX-V:IGX) closed a private placement of 320 units at a price of $10,000 (U.S.) a unit for gross proceeds of $3.2-million. Proceeds will be used for the company’s Montelukast Phase 2a...

H.C. Wainwright analyst Raghuram Selvaraju assumed coverage of CytRx (NASDAQ:CYTR) with a “buy” rating and price target of $4. The stock was quoted at $1.91 in afternoon trading on April 7. CytRx’s two principal value...

Mackie Research initiated coverage of Cannabis Wheaton with a “buy” rating and $3 price target. The stock closed at $1.56 on April 2. Analyst Greg McLeish writes that Wheaton’s “unique model is made up of three distinct...

Roth Capital Partners initiated coverage of Oryzon Genomics (ISIN Code: ES0167733015, ORY) with a “buy” rating and price target of €15. The stock was recently quoted at €2.38. “In our view, the Spanish biotech Oryzon is...